IgG subclasses and allotypes: From structure to effector functions

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Vidarsson, Gestur ^a   Dekkers, Gillian ^a   Rispens, Theo ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Fc receptors; Genetic; Glycosylation; IgG; Immunoglobulin G; Neonatal Fc receptor; Polymorphism

Indexed keywords

CD16 ANTIGEN; CD209 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR LIKE PROTEIN; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN SUBCLASS; PROTEIN; TRIPARTITE MOTIF CONTAINING PROTEIN 21; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CHEMICAL MODIFICATION; COMPLEMENT ACTIVATION; CYTOTOXICITY; DISULFIDE BOND; FUCOSYLATION; GALACTOSYLATION; GLYCOSYLATION; HINGE REGION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; INNATE IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIALYLATION;

EID: 84918825382     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00520     Document Type: Article

References (216)

1. Schur PH. IgG subclasses. A historical perspective. Monogr Allergy (1988) 23:1-11.
2. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113(16):3716-25. doi:10.1182/blood-2008-09-179754
3. Pan Q, Hammarstrom L. Molecular basis of IgG subclass deficiency. Immunol Rev (2000) 178:99-110. doi:10.1034/j.1600-065X.2000.17815.x
4. Vlug A, Nieuwenhuys EJ, van Eijk RV, Geertzen HG, van Houte AJ. Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris) (1994) 52(7-8):561-7.
5. Pone EJ, Zhang J, Mai T, White CA, Li G, Sakakura JK, et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway. Nat Commun (2012) 3:767. doi:10.1038/ncomms1769
6. Pone EJ, Zan H, Zhang J, Al-Qahtani A, Xu Z, Casali P. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit Rev Immunol (2010) 30(1):1-29. doi:10.1615/CritRevImmunol.v30.i1.10
7. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood (2011) 118(8):2150-8. doi:10.1182/blood-2011-04-345579
8. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy (2009) 39(4):469-77. doi:10.1111/j.1365-2222.2009.03207.x
9. Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J (1990) 9(8 Suppl):S16-24. doi:10.1097/00006454-199008001-00004
10. Jefferis R, Kumararatne DS. Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol (1990) 81(3):357-67. doi:10.1111/j.1365-2249.1990.tb05339.x
11. Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med (1980) 303(4):178-82. doi:10.1056/NEJM198007243030402
12. Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol (1986) 63(1):127-34.
13. Schauer U, Stemberg F, Rieger CH, Buttner W, Borte M, Schubert S, et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol (2003) 10(2):202-7. doi:10.1128/CDLI.10.2.202-207.2003
14. Hammarstrom L, Smith CI. IgG2 deficiency in a healthy blood donor. Concomitant lack of IgG2, IgA and IgE immunoglobulins and specific anti-carbohydrate antibodies. Clin Exp Immunol (1983) 51(3):600-4.
15. Hammarstrom L, Carbonara AO, DeMarchi M, Lefranc G, Moller G, Smith CI, et al. Subclass restriction pattern of antigen-specific antibodies in donors with defective expression of IgG or IgA subclass heavy chain constant region genes. Clin Immunol Immunopathol (1987) 45(3):461-70. doi:10.1016/0090-1229(87)90097-3
16. Kuijpers TW, Weening RS, Out TA. IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens. Allergol Immunopathol (Madr) (1992) 20(1):28-34.
17. Latiff AH, Kerr MA. The clinical significance of immunoglobulin A deficiency. Ann Clin Biochem (2007) 44(Pt 2):131-9. doi:10.1258/000456307780117993
18. von Gunten S, Smith DF, Cummings RD, Riedel S, Miescher S, Schaub A, et al. Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. J Allergy Clin Immunol (2009) 123(6):1268-76. doi:10.1016/j.jaci.2009.03.013
19. Vidarsson G, Sigurdardottir ST, Gudnason T, Kjartansson S, Kristinsson KG, Ingolfsdottir G, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun (1998) 66(6):2866-70.
20. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun (2011) 2:599. doi:10.1038/ncomms1608
21. Seppala IJ, Sarvas H, Makela O. Low concentrations of Gm allotypic subsets G3 mg and G1 mf in homozygotes and heterozygotes. J Immunol (1993) 151(5):2529-37.
22. Hassan MS, Islam KB, Hammarstrom L, Smith CI. Regulation of C gamma 3 expression. Role of switch in the allotype-associated variation of human serum IgG3 levels. J Immunol (1992) 148(8):2555-62.
23. Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs (2010) 2(3):212-20. doi:10.4161/mabs.2.3.11780
24. Soderstrom T, Enskog A, Samuelsson BE, Cedergren B. Immunoglobulin subclass (IgG3) restriction of anti-P and anti-Pk antibodies in patients of the rare p blood group. J Immunol (1985) 134(1):1-3.
25. Brouwers HA, Overbeeke MA, Ouwehand WH, Keuning K, van Ertbruggen I, van Leeuwen EF, et al. Maternal antibodies against fetal blood group antigens A or B: lytic activity of IgG subclasses in monocyte-driven cytotoxicity and correlation with ABO haemolytic disease of the newborn. Br J Haematol (1988) 70(4):465-9. doi:10.1111/j.1365-2141.1988.tb02518.x
26. Mawas F, Wiener E, Williamson LM, Rodeck CH. Immunoglobulin G subclasses of anti-human platelet antigen 1a in maternal sera: relation to the severity of neonatal alloimmune thrombocytopenia. Eur J Haematol (1997) 59(5):287-92. doi:10.1111/j.1600-0609.1997.tb01688.x
27. Pollock JM, Bowman JM. Anti-Rh (D) IgG subclasses and severity of Rh hemolytic disease of the newborn. Vox Sang (1990) 59(3):176-9. doi:10.1111/j.1423-0410.1990.tb00854.x
28. Meyts I, Bossuyt X, Proesmans M, Boeck KD. Isolated IgG3 deficiency in children: to treat or not to treat? Case presentation and review of the literature. Pediatr Allergy Immunol (2006) 17(7):544-50. doi:10.1111/j.1399-3038.2006.00454.x
29. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol (1983) 130:722-6.
30. Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, van Leeuwen J. IgG4 as a blocking antibody. Clin Rev Allergy (1983) 1(2):289-302.
31. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 172(5):3252-9. doi:10.4049/jimmunol.172.5.3252
32. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy (2011) 66(6):725-32. doi:10.1111/j.1398-9995.2011.02589.x
33. van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol (2008) 142(4):644-52. doi:10.1111/j.1365-2141.2008.07232.x
34. Andersen BR, Terry WD. Gamma G4-globulin antibody causing inhibition of clotting factor VIII. Nature (1968) 217(5124):174-5. doi:10.1038/217174a0
35. Iizuka A, Nagao T. Analysis of IgG heavy chain subclasses of alloantibodies to factor IX by crossed immunoelectrophoresis of factor IX using the intermediate gel technique. Br J Haematol (1983) 53(4):687-8. doi:10.1111/j.1365-2141.1983.tb07323.x
36. van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, et al. IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients. J Clin Immunol (2012) 32:1000-6. doi:10.1007/s10875-012-9705-0
37. Ottesen EA, Skvaril F, Tripathy SP, Poindexter RW, Hussain R. Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol (1985) 134(4):2707-12.
38. Adjobimey T, Hoerauf A. Induction of immunoglobulin G4 in human filariasis: an indicator of immunoregulation. Ann Trop Med Parasitol (2010) 104(6):455-64. doi:10.1179/136485910X12786389891407
39. Kurniawan A, Yazdanbakhsh M, van Ree R, Aalberse R, Selkirk ME, Partono F, et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol (1993) 150(9):3941-50.
40. Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol (2011) 23(1):108-13. doi:10.1097/BOR.0b013e3283413469
41. Yamamoto M, Tabeya T, Naishiro Y, Yajima H, Ishigami K, Shimizu Y, et al. Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol (2012) 22(3):419-25. doi:10.1007/s10165-011-0532-6
42. Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol (2014) 9:315-47. doi:10.1146/annurev-pathol-012513-104708
43. Potter M. Structural correlates of immunoglobulin diversity. Surv Immunol Res (1983) 2(1):27-42.
44. Wu TT, Johnson G, Kabat EA. Length distribution of CDRH3 in antibodies. Proteins (1993) 16(1):1-7. doi:10.1002/prot.340160102
45. Kabat EA, Wu TT, Bilofsky H. Variable region genes for the immunoglobulin framework are assembled from small segments of DNA - a hypothesis. Proc Natl Acad Sci U S A (1978) 75(5):2429-33. doi:10.1073/pnas.75.5.2429
46. Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc{gamma}RIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 108(31):12669-74. doi:10.1073/pnas.1108455108
47. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 276(19):16469-77. doi:10.1074/jbc.M100350200
48. Kato K, Sautes-Fridman C, Yamada W, Kobayashi K, Uchiyama S, Kim H, et al. Structural basis of the interaction between IgG and Fcgamma receptors. J Mol Biol (2000) 295(2):213-24. doi:10.1006/jmbi.1999.3351
49. Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol (2002) 38(14):1073-83. doi:10.1016/S0161-5890(02)00036-6
50. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A (2013) 110(24):9868-72. doi:10.1073/pnas.1307864110
51. West AP Jr, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor (,). Biochemistry (2000) 39(32):9698-708. doi:10.1021/bi000749m
52. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature (1994) 372(6504):379-83. doi:10.1038/372379a0
53. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci U S A (2008) 105(16):6045-50. doi:10.1073/pnas.0800159105
54. Kapur R, Kustiawan I, Vestrheim A, Koeleman C, Visser R, Einarsdottir HK, et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood (2014) 123(4):471-80. doi:10.1182/blood-2013-09-527978
55. Wuhrer M, Porcelijn L, Kapur R, Koeleman CA, Deelder A, de Haas M, et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res (2009) 8(2):450-6. doi:10.1021/pr800651j
56. Wright A, Tao MH, Kabat EA, Morrison SL. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J (1991) 10(10):2717-23.
57. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest (2013) 123(5):2183-92. doi:10.1172/JCI65708DS1
58. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One (2011) 6(6):e21246. doi:10.1371/journal.pone.0021246
59. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HJ, et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics (2009) 9(17):4143-53. doi:10.1002/pmic.200800931
60. Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem (2007) 282(10):7405-15. doi:10.1074/jbc.M602690200
61. Hamilton RG. Human IgG subclass measurements in the clinical laboratory. Clin Chem (1987) 33(10):1707-25.
62. Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol (1997) 159(7):3372-82.
63. Michaelsen TE, Naess LM, Aase A. Human IgG3 is decreased and IgG1, IgG2 and IgG4 are unchanged in molecular size by mild reduction and reoxidation without any major change in effector functions. Mol Immunol (1993) 30(1):35-45. doi:10.1016/0161-5890(93)90424-A
64. Saluk PH, Clem LW. The unique molecular weight of the heavy chain from human IgG3. J Immunol (1971) 107(1):298-301.
65. Carrasco B, Garcia de la Torre J, Davis KG, Jones S, Athwal D, Walters C, et al. Crystallohydrodynamics for solving the hydration problem for multi-domain proteins: open physiological conformations for human IgG. Biophys Chem (2001) 93(2-3):181-96. doi:10.1016/S0301-4622(01)00220-4
66. Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem (2008) 283(23):16194-205. doi:10.1074/jbc.M709987200
67. Zhang B, Harder AG, Connelly HM, Maheu LL, Cockrill SL. Determination of Fab-hinge disulfide connectivity in structural isoforms of a recombinant human immunoglobulin G2 antibody. Anal Chem (2010) 82(3):1090-9. doi:10.1021/ac902466z
68. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem (2008) 283(23):16206-15. doi:10.1074/jbc.M709988200
69. Lightle S, Aykent S, Lacher N, Mitaksov V, Wells K, Zobel J, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Sci (2010) 19(4):753-62. doi:10.1002/pro.352
70. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol (2003) 170(6):3134-8. doi:10.4049/jimmunol.170.6.3134
71. Chivers PT, Prehoda KE, Raines RT. The CXXC motif: a rheostat in the active site. Biochemistry (1997) 36(14):4061-6. doi:10.1021/bi9628580
72. Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci (1997) 6(2):407-15. doi:10.1002/pro.5560060217
73. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol (1993) 30(1):105-8. doi:10.1016/0161-5890(93)90432-B
74. Rispens T, Ooijevaar-de Heer P, Bende O, Aalberse RC. Mechanism of immunoglobulin G4 Fab-arm exchange. J Am Chem Soc (2011) 133(26):10302-11. doi:10.1021/ja203638y
75. Van der Zee JS, Van Swieten P, Aalberse RC. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol (1986) 137(11):3566-71.
76. van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 317(5844):1554-7. doi:10.1126/science.1144603
77. Rispens T, Davies AM, Ooijevaar-de Heer P, Absalah S, Bende O, Sutton BJ, et al. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem (2014) 289(9):6098-109. doi:10.1074/jbc.M113.541813
78. Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol (2011) 187(6):3238-46. doi:10.4049/jimmunol.1003336
79. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 27(8):767-71. doi:10.1038/nbt.1553
80. Lefranc MP, Lefranc G. Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Methods Mol Biol (2012) 882:635-80. doi:10.1007/978-1-61779-842-9_34
81. de Lange GG. Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogenet (1989) 6(1):7-17.
82. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs (2009) 1(4):332-8. doi:10.4161/mabs.1.4.9122
83. Dard P, Lefranc MP, Osipova L, Sanchez-Mazas A. DNA sequence variability of IGHG3 alleles associated to the main G3m haplotypes in human populations. Eur J Hum Genet (2001) 9(10):765-72. doi:10.1038/sj.ejhg.5200700
84. Brusco A, Saviozzi S, Cinque F, DeMarchi M, Boccazzi C, De LG, et al. Molecular characterization of immunoglobulin G4 gene isoallotypes. Eur J Immunogenet (1998) 25(5):349-55. doi:10.1111/j.1744-313X.1998.tb01152.x
85. Brusco A, de Lange GG, Boccazzi C, Carbonara AO. Molecular characterization of Gm (n+) and G2m (n-) allotypes. Immunogenetics (1995) 42(5):414-7. doi:10.1007/BF00179404
86. de Lange G. Monoclonal Antibodies Against Human Immunoglobulin Allotypes. Ph.D. thesis, University of London, London (1988).
87. Fudenberg HH, Fudenberg BR. Antibody to hereditary human gamma-globulin (Gm) factor resulting from maternal-fetal incompatibility. Science (1964) 145(3628):170-1. doi:10.1126/science.145.3628.170
88. de Lange G, Zhong FM, Henke J, Feng ZC, Bernhardt R, van Leeuwen F, et al. Immunoglobulin allotypes in a Chinese population: comparison of haplotype frequencies with other Asian groups. J Immunogenet (1985) 12(4-5):191-5. doi:10.1111/j.1744-313X.1985.tb00846.x
89. Goetze AM, Zhang Z, Liu L, Jacobsen FW, Flynn GC. Rapid LC-MS screening for IgG Fc modifications and allelic variants in blood. Mol Immunol (2011) 49(1-2):338-52. doi:10.1016/j.molimm.2011.09.002
90. Cook CE, Steinberg AG. An amino acid substitution in the gamma 1 chain of human immunoglobulin G associated with the Gm (2) allotype. Mol Immunol (1979) 16(8):555-8. doi:10.1016/0161-5890(79)90117-2
91. Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, et al. The DNA sequence and analysis of human chromosome 14. Nature (2003) 421(6923):601-7. doi:10.1038/nature01348
92. Hougs L, Garred P, Kawasaki T, Kawasaki N, Svejgaard A, Barington T. Three new alleles of IGHG2 and their prevalence in Danish Caucasians, Mozambican Blacks and Japanese. Tissue Antigens (2003) 61(3):231-9. doi:10.1034/j.1399-0039.2003.00048.x
93. Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study 1. Arthritis Res Ther (2010) 12(6):R221. doi:10.1186/ar3208
94. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab 8. Pharmacogenet Genomics (2009) 19(5):383-7. doi:10.1097/FPC.0b013e32832a06bf
95. Morell A, Skvaril F, Steinberg AG, Van Loghem E, Terry WD. Correlations between the concentrations of the four sub-classes of IgG and Gm allotypes in normal human sera. J Immunol (1972) 108(1):195-206.
96. Iserentant D, Fiers W. Secondary structure of mRNA and efficiency of translation initiation. Gene (1980) 9(1-2):1-12. doi:10.1016/0378-1119(80)90163-8
97. Mao Y, Liu H, Liu Y, Tao S. Deciphering the rules by which dynamics of mRNA secondary structure affect translation efficiency in Saccharomyces cerevisiae. Nucleic Acids Res (2014) 42(8):4813-22. doi:10.1093/nar/gku159
98. Pan Q, Petit-Frere C, Hammarstrom L. An allotype-associated polymorphism in the gamma3 promoter determines the germ-line gamma3 transcriptional rate but does not influence switching and subsequent IgG3 production. Eur J Immunol (2000) 30(8):2388-93. doi:10.1002/1521-4141(2000)30:8<2388::AID-IMMU2388>3.0.CO;2-C
99. Diebolder C, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer M, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 343(6176):1260-3. doi:10.1126/science.1248943
100. Zauner G, Selman MH, Bondt A, Rombouts Y, Blank D, Deelder AM, et al. Glycoproteomic analysis of antibodies. Mol Cell Proteomics (2013) 12(4):856-65. doi:10.1074/mcp.R112.026005
101. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature (1985) 316(6027):452-7. doi:10.1038/316452a0
102. Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, et al. IgG Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics (2014). doi:10.1074/mcp.M114.039537
103. Kapur R, Della Valle L, Sonneveld M, Hipgrave Ederveen A, Visser R, Ligthart P, et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol (2014) 166(6):936-45. doi:10.1111/bjh.12965
104. Menni C, Keser T, Mangino M, Bell JT, Erte I, Akmacic I, et al. Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. PLoS One (2013) 8(12):e82558. doi:10.1371/journal.pone.0082558
105. Chen G, Wang Y, Qiu L, Qin X, Liu H, Wang X, et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics (2012) 75(10):2824-34. doi:10.1016/j.jprot.2012.02.001
106. Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, Selman MH, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics (2011) 10(5):M110. doi:10.1074/mcp.M110.004655
107. Prados MB, La Blunda J, Szekeres-Bartho J, Caramelo J, Miranda S. Progesterone induces a switch in oligosaccharyltransferase isoform expression: consequences on IgG N-glycosylation. Immunol Lett (2011) 137(1-2):28-37. doi:10.1016/j.imlet.2011.01.017
108. Bowden TA, Baruah K, Coles CH, Harvey DJ, Yu X, Song BD, et al. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J Am Chem Soc (2012) 134(42):17554-63. doi:10.1021/ja306068g
109. Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem (2001) 276(49):45539-47. doi:10.1074/jbc.M107478200
110. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature (2000) 406(6793):267-73. doi:10.1038/35018508
111. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells (2011) 16(11):1071-80. doi:10.1111/j.1365-2443.2011.01552.x
112. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 277(30):26733-40. doi:10.1074/jbc.M202069200
113. Yamane-Ohnuki N, Satoh M. Production of therapeutic antibodies with controlled fucosylation. MAbs (2009) 1(3):230-6. doi:10.4161/mabs.1.3.8328
114. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci (2009) 30(7):356-62. doi:10.1016/j.tips.2009.04.007
115. Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K, et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol (2009) 37(3):309-21. doi:10.1016/j.exphem.2008.11.006
116. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WK, Dechant M, Beyer T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood (2008) 112(6):2390-9. doi:10.1182/blood-2008-03-144600
117. Selman MH, de Jong SE, Soonawala D, Kroon FP, Adegnika AA, Deelder AM, et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics (2012) 11(4):M111. doi:10.1074/mcp.M111.014563
118. Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J (2012) 29(1):57-66. doi:10.1007/s10719-011-9364-z
119. Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang LX. Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcgammaIIIa receptor. J Am Chem Soc (2011) 133(46):18975-91. doi:10.1021/ja208390n
120. Bakovic MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res (2013) 12(2):821-31. doi:10.1021/pr300887z
121. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng (2006) 93(5):851-61. doi:10.1002/bit.20777
122. Kapur R, Einarsdottir HK, Vidarsson G. IgG-effector functions: "the good, the bad and the ugly". Immunol Lett (2014) 160(2):139-44. doi:10.1016/j.imlet.2014.01.015
123. Bondt A, Selman MH, Deelder AM, Hazes JM, Willemsen SP, Wuhrer M, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res (2013) 12(10):4522-31. doi:10.1021/pr400589m
124. Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, et al. Structural characterization of anti-inflammatory immunoglobulin g fc proteins. J Mol Biol (2014) 426(18):3166-79. doi:10.1016/j.jmb.2014.07.006
125. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting frosialylation. Science (2006) 313(5787):670-3. doi:10.1126/science.1129594
126. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 320(5874):373-6. doi:10.1126/science.1154315
127. Sarma JV, Ward PA. The complement system. Cell Tissue Res (2011) 343(1):227-35. doi:10.1007/s00441-010-1034-0
128. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 168(1):127-42. doi:10.1084/jem.168.1.127
129. Schumaker VN, Calcott MA, Spiegelberg HL, Muller-Eberhard HJ. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry (1976) 15(23):5175-81. doi:10.1021/bi00668a035
130. Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 178(2):661-7. doi:10.1084/jem.178.2.661
131. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol (2000) 164(8):4178-84. doi:10.4049/jimmunol.164.8.4178
132. Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology (1995) 86(2):319-24.
133. Brekke OH, Michaelsen TE, Aase A, Sandin RH, Sandlie I. Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. Eur J Immunol (1994) 24(10):2542-7. doi:10.1002/eji.1830241042
134. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol (2006) 177(2):1129-38. doi:10.4049/jimmunol.177.2.1129
135. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J (1988) 7(7):1989-94.
136. Lu Y, Harding SE, Michaelsen TE, Longman E, Davis KG, Ortega A, et al. Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation. Biophys J (2007) 93(11):3733-44. doi:10.1529/biophysj.107.108993
137. Tan LK, Shopes RJ, Oi VT, Morrison SL. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A (1990) 87(1):162-6. doi:10.1073/pnas.87.1.162
138. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res (2008) 68(10):3863-72. doi:10.1158/0008-5472.CAN-07-6297
139. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology (2002) 105(1):9-19. doi:10.1046/j.0019-2805.2001.01341.x
140. Abe Y, Gor J, Bracewell DG, Perkins SJ, Dalby PA. Masking of the Fc region in human IgG4 by constrained X-ray scattering modelling: implications for antibody function and therapy 1. Biochem J (2010) 432(1):101-11. doi:10.1042/BJ20100641
141. Van der Zee JS, Van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol (1986) 64(2):415-22.
142. Saeland E, Vidarsson G, Leusen JH, Van Garderen E, Nahm MH, Vile-Weekhout H, et al. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol (2003) 170(12):6158-64. doi:10.4049/jimmunol.170.12.6158
143. Vidarsson G, Jonsdottir I, Jonsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis (1994) 170:592-9. doi:10.1093/infdis/170.3.592
144. Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol (2011) 187(6):3208-17. doi:10.4049/jimmunol.1101467
145. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fc receptors in dendritic cells and macrophages. Nat Rev Immunol (2014) 14(2):94-108. doi:10.1038/nri3582
146. Ernst LK, van de Winkel JG, Chiu IM, Anderson CL. Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem (1992) 267(22):15692-700.
147. Ernst LK, Duchemin AM, Miller KL, Anderson CL. Molecular characterization of six variant Fcgamma receptor class I (CD64) transcripts. Mol Immunol (1998) 35(14-15):943-54. doi:10.1016/S0161-5890(98)00079-0
148. Hulett MD, Hogarth PM. The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. Mol Immunol (1998) 35(14-15):989-96. doi:10.1016/S0161-5890(98)00069-8
149. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med (1991) 173(6):1483-91. doi:10.1084/jem.173.6.1483
150. Chappel MS, Isenman DE, Everett M, Xu YY, Dorrington KJ, Klein MH. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci U S A (1991) 88(20):9036-40. doi:10.1073/pnas.88.20.9036
151. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2001) 276(9):6591-604. doi:10.1074/jbc.M009483200
152. Lund J, Winter G, Jones PT, Pound JD, Tanaka T, Walker MR, et al. Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG. J Immunol (1991) 147(8):2657-62.
153. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol (1999) 29(8):2613-24. doi:10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J
154. Redpath S, Michaelsen TE, Sandlie I, Clark MR. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Hum Immunol (1998) 59(11):720-7. doi:10.1016/S0198-8859(98)00075-5
155. Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 90(4):1537-46. doi:10.1172/JCI116022
156. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol (2003) 40(9):585-93. doi:10.1016/j.molimm.2003.08.004
157. Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol (2000) 164(10):5313-8. doi:10.4049/jimmunol.164.10.5313
158. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol (2012) 188(3):1318-24. doi:10.4049/jimmunol.1003945
159. Breunis WB, van Mirre E, Bruin M, Geissler J, de BM, Peters M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood (2008) 111(3):1029-38. doi:10.1182/blood-2007-03-079913
160. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol (2006) 24(2):210-5. doi:10.1038/nbt1178
161. Siberil S, de Romeuf C, Bihoreau N, Fernandez N, Meterreau JL, Regenman A, et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol (2006) 118(2-3):170-9. doi:10.1016/j.clim.2005.10.008
162. Huizinga TW, Kleijer M, Tetteroo PA, Roos D, von dem Borne AE. Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phospho-inositol-linked Fc gamma receptor III (CD16). Blood (1990) 75(1):213-7.
163. Huizinga TW, Kerst M, Nuyens JH, Vlug A, von dem Borne AE, Roos D, et al. Binding characteristics of dimeric IgG subclass complexes to human neutrophils. J Immunol (1989) 142(7):2359-64.
164. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature (1964) 203:1352-4. doi:10.1038/2031352a0
165. Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet (1966) 2(7473):1087-93. doi:10.1016/S0140-6736(66)92190-8
166. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol (1996) 26(3):690-6. doi:10.1002/eji.1830260327
167. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology (1996) 89(4):573-8. doi:10.1046/j.1365-2567.1996.d01-775.x
168. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A (1996) 93(11):5512-6. doi:10.1073/pnas.93.11.5512
169. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol (2003) 170(7):3528-33. doi:10.4049/jimmunol.170.7.3528
170. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Biol Chem (2003) 197(3):315-22. doi:10.1084/jem.20021829
171. Gastinel LN, Simister NE, Bjorkman PJ. Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. Proc Natl Acad Sci U S A (1992) 89(2):638-42. doi:10.1073/pnas.89.2.638
172. Einarsdottir H, Ji Y, Visser R, Mo C, Luo G, Scherjon S, et al. H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. Transfusion (2014) 54(3):665-71. doi:10.1111/trf.12334
173. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol (2006) 27(7):343-8. doi:10.1016/j.it.2006.05.004
174. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol (1998) 10(9):1289-98. doi:10.1093/intimm/10.9.1289
175. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol (2007) 179(7):4580-8. doi:10.4049/jimmunol.179.7.4580
176. Kacskovics I, Cervenak J, Erdei A, Goldsby RA, Butler JE. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies. MAbs (2011) 3(5):431-9. doi:10.4161/mabs.3.5.17023
177. Yoshida M, Claypool SM, Wagner JS, Mizoguchi E, Mizoguchi A, Roopenian DC, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004) 20(6):769-83. doi:10.1016/j.immuni.2004.05.007
178. Israel EJ, Patel VK, Taylor SF, Marshak-Rothstein A, Simister NE. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol (1995) 154(12):6246-51.
179. Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology (1997) 92(1):69-74. doi:10.1046/j.1365-2567.1997.00326.x
180. Ladinsky MS, Huey-Tubman KE, Bjorkman PJ. Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestine. Mol Biol Cell (2012) 23(13):2537-45. doi:10.1091/mbc.E12-02-0093
181. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med (2002) 196(3):303-10. doi:10.1084/jem.20020400
182. Claypool SM, Dickinson BL, Wagner JS, Johansen FE, Venu N, Borawski JA, et al. Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor. Mol Biol Cell (2004) 15(4):1746-59. doi:10.1091/mbc.E03-11-0832
183. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest (1999) 104(7):903-11. doi:10.1172/JCI6968
184. Shah U, Dickinson BL, Blumberg RS, Simister NE, Lencer WI, Walker WA. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatr Res (2003) 53(2):295-301. doi:10.1203/01.PDR.0000047663.81816.E3
185. Caram-Salas N, Boileau E, Farrington GK, Garber E, Brunette E, Abulrob A, et al. In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier. Methods Mol Biol (2011) 763:383-401. doi:10.1007/978-1-61779-191-8_26
186. Robert-Guroff M. IgG surfaces as an important component in mucosal protection. Nat Med (2000) 6(2):129-30. doi:10.1038/72206
187. Yoshida M, Kobayashi K, Kuo TT, Bry L, Glickman JN, Claypool SM, et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest (2006) 116(8):2142. doi:10.1172/JCI27821.2142
188. Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol (2013) 4:200. doi:10.3389/fimmu.2013.00200
189. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol (2001) 166(5):3266-76. doi:10.4049/jimmunol.166.5.3266
190. Cervenak J, Bender B, Schneider Z, Magna M, Carstea BV, Liliom K, et al. Neonatal FcR overexpression boosts humoral immune response in transgenic mice. J Immunol (2011) 186(2):959-68. doi:10.4049/jimmunol.1000353
191. Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood (2006) 108(10):3573-9. doi:10.1182/blood-2006-05-024539
192. Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2011) 108(24):9927-32. doi:10.1073/pnas.1019037108
193. Mi W, Wanjie S, Lo ST, Gan Z, Pickl-Herk B, Ober RJ, et al. Targeting the neonatal Fc receptor for antigen delivery using engineered Fc fragments. J Immunol (2008) 181(11):7550. doi:10.4049/jimmunol.181.11.7550
194. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A (2008) 105(27):9337-42. doi:10.1073/pnas.0801717105
195. Heijnen I, van Vugt MJ, Fanger N, Graziano RF, de Wit TP, Hofhuis FM, et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest (1996) 97(2):331-8. doi:10.1172/JCI118420
196. Ehrhardt GR, Davis RS, Hsu JT, Leu CM, Ehrhardt A, Cooper MD. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U S A (2003) 100(23):13489-94. doi:10.1073/pnas.1935944100
197. Haga CL, Ehrhardt GR, Boohaker RJ, Davis RS, Cooper MD. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci U S A (2007) 104(23):9770-5. doi:10.1073/pnas.0703354104
198. Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol (2006) 18(9):1363-73. doi:10.1093/intimm/dxl069
199. Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med (2005) 202(6):783-91. doi:10.1084/jem.20050879
200. Frank MB, Itoh K, Fujisaku A, Pontarotti P, Mattei MG, Neas BR. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms. Am J Hum Genet (1993) 52(1):183-91.
201. Yang YS, Yang MC, Wang B, Weissler JC. Autoantigen Ro52 directly interacts with human IgG heavy chain in vivo in mammalian cells. Mol Immunol (2000) 37(10):591-602. doi:10.1016/S0161-5890(00)00068-7
202. Rhodes D, Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol (2007) 44(9):2406-14. doi:10.1016/j.molimm.2006.10.013
203. Vaysburd M, Watkinson RE, Cooper H, Reed M, O'Connell K, Smith J, et al. Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Natl Acad Sci U S A (2013) 110(30):12397-401. doi:10.1073/pnas.1301918110
204. Watkinson RE, Tam JC, Vaysburd MJ, James LC. Simultaneous neutralization and innate immune detection of a replicating virus by TRIM21. J Virol (2013) 87(13):7309-13. doi:10.1128/JVI.00647-13
205. Rakebrandt N, Lentes S, Neumann H, James LC, Neumann-Staubitz P. Antibody- and TRIM21-dependent intracellular restriction of Salmonella enterica. Pathog Dis (2014). doi:10.1111/2049-632X.12192
206. Mallery DL, McEwan W, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A (2010) 107(46):19985-90. doi:10.1073/pnas.1014074107
207. McEwan W, Mallery DL, Rhodes D, Trowsdale J, James LC. Intracellular antibody-mediated immunity and the role of TRIM21. Bioessays (2011) 33(11):803-9. doi:10.1002/bies.201100093
208. McEwan W, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol (2013) 14(4):327-36. doi:10.1038/ni.2548
209. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T (H)2 pathway. Nature (2011) 475(7354):110-3. doi:10.1038/nature10134
210. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A (2008) 105(50):19571-8. doi:10.1073/pnas.0810163105
211. Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol (2014) 133(3):853-63. doi:10.1016/j.jaci.2013.09.029
212. Yu X, Vasiljevic S, Mitchell D, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol (2013) 425(8):1253-8. doi:10.1016/j.jmb.2013.02.006
213. von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood (2006) 108(13):4255-9. doi:10.1182/blood-2006-05-021568
214. von Gunten S, Vogel M, Schaub A, Stadler BM, Miescher S, Crocker PR, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol (2007) 119(4):1005-11. doi:10.1016/j.jaci.2007.01.023
215. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood (2010) 116(10):1698-704. doi:10.1182/blood-2009-12-261461
216. Schaub A, von Gunten S, Vogel M, Wymann S, Ruegsegger M, Stadler BM, et al. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy (2011) 66(8):1030-7. doi:10.1111/j.1398-9995.2011.02579.x